Form 8-K - Current report:
SEC Accession No. 0001703057-26-000010
Filing Date
2026-02-24
Accepted
2026-02-24 16:15:09
Documents
29
Period of Report
2026-02-24
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K abcl-20260224.htm   iXBRL 8-K 27395
2 EX-99.1 a2025earningspressrelease.htm EX-99.1 175256
3 EX-99.2 a2025q4fybusinessupdatef.htm EX-99.2 13696
7 a2025q4fybusinessupdatef001.jpg GRAPHIC 49008
8 a2025q4fybusinessupdatef002.jpg GRAPHIC 106165
9 a2025q4fybusinessupdatef003.jpg GRAPHIC 114599
10 a2025q4fybusinessupdatef004.jpg GRAPHIC 86719
11 a2025q4fybusinessupdatef005.jpg GRAPHIC 72045
12 a2025q4fybusinessupdatef006.jpg GRAPHIC 103976
13 a2025q4fybusinessupdatef007.jpg GRAPHIC 89268
14 a2025q4fybusinessupdatef008.jpg GRAPHIC 66602
15 a2025q4fybusinessupdatef009.jpg GRAPHIC 80077
16 a2025q4fybusinessupdatef010.jpg GRAPHIC 79806
17 a2025q4fybusinessupdatef011.jpg GRAPHIC 69286
18 a2025q4fybusinessupdatef012.jpg GRAPHIC 58838
19 a2025q4fybusinessupdatef013.jpg GRAPHIC 46677
20 a2025q4fybusinessupdatef014.jpg GRAPHIC 61964
21 a2025q4fybusinessupdatef015.jpg GRAPHIC 64040
  Complete submission text file 0001703057-26-000010.txt   1931180

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT abcl-20260224.xsd EX-101.SCH 1788
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT abcl-20260224_lab.xml EX-101.LAB 20678
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT abcl-20260224_pre.xml EX-101.PRE 11962
32 EXTRACTED XBRL INSTANCE DOCUMENT abcl-20260224_htm.xml XML 2796
Mailing Address 150 W 4TH AVENUE VANCOUVER A1 V5Y 1G6
Business Address 150 W 4TH AVENUE VANCOUVER A1 V5Y 1G6 (604) 559-9005
AbCellera Biologics Inc. (Filer) CIK: 0001703057 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39781 | Film No.: 26671759
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)